Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neoplasms 2Stomach Neoplasms 1Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Complications 1Noncommunicable Diseases 1Neoplasms, Squamous Cell 1Neoplasms, Basal Cell 1Melanoma 1Lymphatic Abnormalities 1Lymphangioma 1Ischemic Stroke 1Chronic Disease 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1Brain Neoplasms 1Abdomen, Acute 1

Interventions

Nivolumab 13Ipilimumab 10pembrolizumab 8cemiplimab 6Surveys and Questionnaires 6Biopsy 6aldesleukin 5Radiotherapy 5Interleukin-2 5Blood Specimen Collection 5Temozolomide 4Sirolimus 4Photochemotherapy 4Mohs Surgery 4HhAntag691 4Fluorouracil 4Educational Status 4Cyclophosphamide 4sonidegib 3fludarabine phosphate 3fludarabine 3avelumab 3Vemurafenib 3Surgical Procedures, Operative 3Radiation 3Petrolatum 3Cetuximab 3Aminolevulinic Acid 3trametinib 2dabrafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Skin Neoplasms × Risk Factors × Clear all
NCT03509467 2025-12-19

Using MC1R Genotype to Impact Melanoma Risk Behavior

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Completed
2,054 enrolled 92 charts
Dermatologic

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasms, Neoplasms, Basal Cell, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡